Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133391) titled 'A Clinical Study of Polatuzumab Vedotin-Based Combination Regimen for Low-Risk Large B-Cell Lymphoma' on Sept. 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Previously untreated, low-risk (International Prognostic Index [IPI] 0-1) diffuse large B-cell lymphoma (DLBCL)
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-01
Target Sample Size: Pola-R-CHP Induction and Sequential Therapy Group:50;
Countries of Recruitment:
China
To know more, vi...